EpiBiologics website screenshot

EpiBiologics

EpiBiologics is a clinical-stage biotechnology company based in San Mateo, California, developing bispecific antibodies for directed extracellular protein degradation. Its proprietary EpiTAC platform leverages an atlas of 270+ degradation-inducing cell-surface receptors to build tissue-selective therapies that degrade disease-causing proteins while sparing healthy tissue, targeting cancer, autoimmune, and other serious diseases. The company dosed its first patient with EPI-326 (an EGFR-driven solid-tumor bispecific) in a Phase 1 study in April 2026 and closed a $107M Series B round in January 2026. Backed by GV, EpiBiologics was added to the API Evangelist network as a portfolio-lead profile; it publishes a corporate website but no public developer/API surface.

EpiBiologics is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Therapeutics, and Drug Discovery.

EpiBiologics’ developer surface includes support and 3 more developer resources.

🌐 Visit website 📡 Source on GitHub
4.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyLife SciencesBiotechnologyTherapeuticsDrug DiscoveryProtein DegradationAntibodiesOncology

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 4.3/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.8 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 1.1 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/epibiologics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Epibiologics Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Company 2

The organization behind the API

Website
Website
 About
About

Source (apis.yml)

apis.yml Raw ↑ 
aid: epibiologics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/epibiologics.png
name: EpiBiologics
description: EpiBiologics is a clinical-stage biotechnology company based in San Mateo, California, developing bispecific
  antibodies for directed extracellular protein degradation. Its proprietary EpiTAC platform leverages an atlas of 270+ degradation-inducing
  cell-surface receptors to build tissue-selective therapies that degrade disease-causing proteins while sparing healthy tissue,
  targeting cancer, autoimmune, and other serious diseases. The company dosed its first patient with EPI-326 (an EGFR-driven
  solid-tumor bispecific) in a Phase 1 study in April 2026 and closed a $107M Series B round in January 2026. Backed by GV,
  EpiBiologics was added to the API Evangelist network as a portfolio-lead profile; it publishes a corporate website but no
  public developer/API surface.
url: https://raw.githubusercontent.com/api-evangelist/epibiologics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Biotechnology
- Therapeutics
- Drug Discovery
- Protein Degradation
- Antibodies
- Oncology
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.epibiologics.com
- type: About
  url: https://www.epibiologics.com/about-us
- type: Support
  url: https://www.epibiologics.com/contact
- type: DomainSecurity
  url: security/epibiologics-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence